ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2382

Evaluation of Intestinal Inflammation in Children with FMF

Ozge Altug-Gucenmez, Tuncay Kume, Balahan Makay, Omur Babayigit, Nur Arslan and Erbil Unsal, Dokuz Eylul University, Izmir, Turkey

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Bowel, familial Mediterranean fever and inflammation

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster III: Systemic JIA, Autoinflammatory Syndromes, Scleroderma, Vasculitis, Miscellaneous

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Familial Mediterranean Fever (FMF) is the most common auto-inflammatory disease with recurrent fever and serositis episodes. Abnormal pyrin protein due to MEFV gene mutations leads to clinical symptoms in FMF. Abdominal attacks happen due to the serosal inflammation in FMF. The sterile exudate which includes fibrin and polimorphonuclear cells occurs in the peritoneal space. Other gastrointestinal symptoms such as irritable bowel disease, colchicine related diarrhea and amyloidosis related malabsorption can be also detected. The rate of inflammatory bowel disease (IBD) is also shown to be increased in FMF. In recent years, some cases with FMF were reported with gastrointestinal involvement without amyloidosis, vasculitis and IBH. It is not yet known, whether the gastrointestinal involvement is a part of the disease or not. The aim of this study is to investigate the frequency of intestinal inflammation by using a noninvasive method, fecal calprotectin measurement, in pediatric FMF patients.

Methods: Sixty-five FMF patients, 30 healthy controls and 11 control patients with ulcerative colitis were included in the study. A standard survey which including gastrointestinal and other clinical symptoms and medications was used. MEFV mutations, whole blood count and CRP levels were recorded. Fecal calprotectin was studied with the ELISA method from the feces samples of the all patients. The upper cutoff value was determined as 200 ug/g.

Results: The patients were similar in terms of age and gender among groups. None of the FMF patients had clinical signs of the IBD. Fecal calprotectin levels of the FMF patients were found significantly higher than the healthy controls (174.8 ± 150.8 vs 52.9 ± 36.5, p< 0.001). In contrast, fecal calprotectin levels of the ulcerative colitis patients were significantly higher than the FMF patients (523.5 ± 183 vs 174.8 ± 150.8, p< 0.001). Even though, there are no IBD signs, the fecal calprotectin levels were higher than the cutoff point in 19 of the FMF patients. There was a correlation between fecal calprotectin levels and neutrophil/lymphocyte ratio (r=0.324, p=0.009).

Conclusion: Our results supported the subclinical intestinal inflammation in pediatric FMF patients. Underlying chronic auto-inflammatory process or continuous colchicine usage could result this observation. Further studies are needed to clarify the reason of the intestinal inflammation in FMF patients.


Disclosure: O. Altug-Gucenmez, None; T. Kume, None; B. Makay, None; O. Babayigit, None; N. Arslan, None; E. Unsal, None.

To cite this abstract in AMA style:

Altug-Gucenmez O, Kume T, Makay B, Babayigit O, Arslan N, Unsal E. Evaluation of Intestinal Inflammation in Children with FMF [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/evaluation-of-intestinal-inflammation-in-children-with-fmf/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-intestinal-inflammation-in-children-with-fmf/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology